Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2018 Apr 25;17(7):1602–1612. doi: 10.1158/1535-7163.MCT-17-1066

Figure 4. Drug dose and treatment duration impact host TIS.

Figure 4

(A) Protein levels of circulating sVEGFR2, VEGF, and PlGF2 after treatment with varying doses of Sunitinib, Sorafenib, Pazopanib, Axitinib, and Vandetanib (Balb/c mice; n= 3-16; 7-day treatment). (B) Plasma protein levels of OPN, and Leptin after chronic treatment with Sunitinib (40 days), Axitinib, and Crizotinib (58 days) (SCID mice; n= 3-11). * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001 compared to corresponding vehicle treated animals or baseline (Day 0). Note: Sunitinib data shown in Fig 4A for VEGF and sVEGFR-2 is an expansion of results published in Ebos et al., PNAS, 2007 and is shown here for comparative purposes.